Association between vitamin D receptor gene polymorphism and essential hypertension: An updated systematic review, meta-analysis, and meta-regression

被引:0
作者
Dakota, Iwan [1 ]
Adda'i, Muhamad Fajri [1 ]
Maulana, Rido [1 ]
Ivan, Ignatius [2 ]
Sukmawan, Renan [1 ]
Widyantoro, Bambang [1 ]
机构
[1] Univ Indonesia, Fac Med, Natl Cardiovasc Ctr Harapan Kita, Dept Cardiol & Vasc Med, Jakarta, Indonesia
[2] Atma Jaya Catholic Univ Indonesia, Sch Med & Hlth Sci, Jakarta, Indonesia
来源
PLOS ONE | 2024年 / 19卷 / 12期
关键词
PLASMA-RENIN ACTIVITY; 1,25-DIHYDROXYVITAMIN D-3; PUBLICATION BIAS; CELLS; HORMONE; DISEASE; IMPACT; FOKI; APAI;
D O I
10.1371/journal.pone.0314886
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The association between Vitamin D Receptor (VDR) gene polymorphisms and essential hypertension (EH) remains controversial. We searched databases (Cochrane Library, EBSCO, EMBASE, LILACS, ProQuest, PubMed, Science Direct, Springer) for studies on VDR gene polymorphisms and EH until May 30, 2024, following PRISMA guidelines. RevMan 5.4.1 provided pooled odds ratio (OR) under Hardy-Weinberg Equilibrium based on allele, additive, dominant, and recessive genetic models. Meta-regression was performed using Comprehensive Meta Analysis V3. Twenty-two studies from thirteen countries were analyzed. The recessive model suggested lower EH risk in individuals with the recessive allele (bb) of BsmI (OR: 0.81; 95%CI, 0.69 to 0.94, p = 0.007; I-2 = 35%, p = 0.13). No significant associations were found for FokI, ApaI, and TaqI polymorphisms. Methodological quality significantly influenced EH risk associated with the FokI polymorphism across allele, additive, and dominant models (All p<0.0005). Male proportion influenced EH risk in the additive model for the FokI polymorphism (p = 0.0235), while age impacted risk in the recessive model (p = 0.0327). FokI polymorphism's influence on EH risk varies by sex, age, and study quality. BsmI polymorphism is independently associated with lower EH risk in recessive homozygotes, with no significant associations found for ApaI and TaqI polymorphisms.
引用
收藏
页数:25
相关论文
共 65 条
[1]  
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J., Global burden of hypertension: analysis of worldwide data, Lancet, 365, pp. 217-223, (2005)
[2]  
Mohan V, Seedat YK, Pradeepa R., The rising burden of diabetes and hypertension in southeast asian and african regions: need for effective strategies for prevention and control in primary health care settings, Int J Hypertens, 2013, (2013)
[3]  
Butler MG., Pediatric hypertension: Genetics of hypertension• current status, J Med Liban, 58, (2010)
[4]  
Jiang LL, Zhang C, Zhang Y, Ma F, Guan Y., Associations between polymorphisms in VDR gene and the risk of osteoporosis: a meta-analysis, Arch Physiol Biochem, 128, pp. 1637-1644, (2022)
[5]  
Li L, Wu B, Liu J-Y, Yang L-B., Vitamin D receptor gene polymorphisms and type 2 diabetes: a meta-analysis, Arch Med Res, 44, pp. 235-241, (2013)
[6]  
Imani D, Razi B, Motallebnezhad M, Rezaei R., Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis, BMC Neurol, 19, pp. 1-17, (2019)
[7]  
Xiong J, He Z, Zeng X, Zhang Y, Hu Z., Association of vitamin D receptor gene polymorphisms with systemic lupus erythematosus: a meta-analysis, Clin Exp Rheumatol, 32, pp. 174-181, (2014)
[8]  
Ferrer-Suay S, Alonso-Iglesias E, Tortajada-Girbes M, Carrasco-Luna J, Codoner-Franch P., Vitamin D receptor gene ApaI and FokI polymorphisms and its association with inflammation and oxidative stress in vitamin D sufficient Caucasian Spanish children, Transl Pediatr, 10, (2021)
[9]  
Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Et al., Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1, 25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries, J Clin Invest, 83, pp. 1903-1915, (1989)
[10]  
Saponaro F, Marcocci C, Zucchi R., Vitamin D status and cardiovascular outcome, J Endocrinol Invest, 42, pp. 1285-1290, (2019)